DGIdb - FLUOROURACIL Drug Record

FLUOROURACIL chembl:CHEMBL185 ApprovedAntineoplasticImmunotherapy

Alternate Names:

FLURACIL
ACTIKERALL
CARAC
EFUDEX
FLUOROPLEX
ACCUSITE
RO-29757
5.F.U.
FLUORO-URACIL ROCHE
NSC-19893
5 FU
ADRUCIL
EFUDIX
TOLAK
5-FU
5-FLUOROURACIL
RO-2-9757
FLUOROURACIL
FLUOROURACILO
FLUORURACIL
CARAC®
FLUOURACIL
FU
FLUOROURACILUM
FLUORO URACIL
5-FLUORACIL
5-FLUOROPYRIMIDINE-2,4-DIONE
5-FLURACIL
ADRUCIL®
rxcui:4492
pubchem.compound:3385
drugbank:00544
chemidplus:51-21-8
chembl:CHEMBL185

Drug Info:

(10 More Sources)

Publications:

Kalra S et al., 2018, Association of CYP2C192 and ALDH1A11/*2 variants with disease outcome in breast cancer patients: results of a global screening array., Eur J Clin Pharmacol
Geng R et al., 2014, Oxidative stress-related genetic polymorphisms are associated with the prognosis of metastatic gastric cancer patients treated with epirubicin, oxaliplatin and 5-fluorouracil combination chemotherapy., PLoS One
Choi JY et al., 2009, Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial., Clin Cancer Res
Nikas et al., 2015, A common variant in MTHFR influences response to chemoradiotherapy and recurrence of rectal cancer., Am J Cancer Res
Huang et al., 2009, The polymorphisms of TS and MTHFR predict survival of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population., Cancer Chemother. Pharmacol.
Yousef AM et al., 2018, The association of polymorphisms in folate-metabolizing genes with response to adjuvant chemotherapy of colorectal cancer., Cancer Chemother Pharmacol
Nahid NA et al., 2018, DPYD*2A and MTHFR C677T predict toxicity and efficacy, respectively, in patients on chemotherapy with 5-fluorouracil for colorectal cancer., Cancer Chemother Pharmacol
Meulendijks D et al., 2017, Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies., Pharmacogenomics J
Roberto M et al., 2017, Evaluation of 5-fluorouracil degradation rate and Pharmacogenetic profiling to predict toxicity following adjuvant Capecitabine., Eur J Clin Pharmacol
Borro M et al., 2017, Pre-treatment assay of 5-fluorouracil degradation rate (5-FUDR) to improve prediction of 5-fluorouracil toxicity in gastro-esophageal cancer., Oncotarget
Romiti A et al., 2016, The TYMS-TSER polymorphism is associated with toxicity of low-dose capecitabine in patients with advanced gastrointestinal cancer., Anticancer Drugs
Mazzuca F et al., 2016, Pre-treatment evaluation of 5-fluorouracil degradation rate: association of poor and ultra-rapid metabolism with severe toxicity in a colorectal cancer patients cohort., Oncotarget
Chaturvedi P et al., 2015, Relationship of MTHFR and NQO1 Pharmacogenetics and Chemotherapy Clinical Outcomes in Breast Cancer Patients., Biochem Genet
Cecchin E et al., 2015, MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin., Pharmacogenomics J
Custodio A et al., 2014, Pharmacogenetic predictors of outcome in patients with stage II and III colon cancer treated with oxaliplatin and fluoropyrimidine-based adjuvant chemotherapy., Mol Cancer Ther
Jennings BA et al., 2013, Evaluating predictive pharmacogenetic signatures of adverse events in colorectal cancer patients treated with fluoropyrimidines., PLoS One
Loganayagam A et al., 2013, Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity., Br J Cancer
van Huis-Tanja LH et al., 2013, MTHFR polymorphisms and capecitabine-induced toxicity in patients with metastatic colorectal cancer., Pharmacogenet Genomics
Lee KH et al., 2013, Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer., Cancer Chemother Pharmacol
Kristensen MH et al., 2010, Variants in the dihydropyrimidine dehydrogenase, methylenetetrahydrofolate reductase and thymidylate synthase genes predict early toxicity of 5-fluorouracil in colorectal cancer patients., J Int Med Res
Henríquez-Hernández LA et al., 2010, Distribution of TYMS, MTHFR, p53 and MDR1 gene polymorphisms in patients with breast cancer treated with neoadjuvant chemotherapy., Cancer Epidemiol
Boige V et al., 2010, Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05., J Clin Oncol
Gusella M et al., 2009, Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer., Br J Cancer
Schwab M et al., 2008, Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group., J Clin Oncol
Sharma R et al., 2008, Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients., Clin Cancer Res
Capitain O et al., 2008, The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer., Pharmacogenomics J
Schwahn B et al., 2001, Polymorphisms in the methylenetetrahydrofolate reductase gene: clinical consequences., Am J Pharmacogenomics
Ruzzo A et al., 2008, Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy., Pharmacogenomics J
Pelà M et al., 2014, Optimization of peptides that target human thymidylate synthase to inhibit ovarian cancer cell growth., J Med Chem
Huang et al., 2006, Tailor-made chemotherapy for non-small cell lung cancer patients., Future Oncol
Garcia et al., 2006, Thymidylate synthase messenger RNA expression in plasma from patients with colon cancer: prognostic potential., Clin. Cancer Res.
Fernández-Contreras et al., 2006, Thymidylate synthase expression pattern, expression level and single nucleotide polymorphism are predictors for disease-free survival in patients of colorectal cancer treated with 5-fluorouracil., Int. J. Oncol.
Formentini et al., 2007, Thymidylate synthase expression in resectable and unresectable pancreatic cancer: role as predictive or prognostic marker?, Int J Colorectal Dis
Ploylearmsaeng et al., 2006, How may anticancer chemotherapy with fluorouracil be individualised?, Clin Pharmacokinet
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Rustum, 2004, Thymidylate synthase: a critical target in cancer therapy?, Front. Biosci.
Martinez-Balibrea et al., 2010, UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy., Br. J. Cancer
Singh V et al., 2015, The complex mechanism of antimycobacterial action of 5-fluorouracil., Chem Biol
Absenger G et al., 2014, The cyclin D1 (CCND1) rs9344 G>A polymorphism predicts clinical outcome in colon cancer patients treated with adjuvant 5-FU-based chemotherapy., Pharmacogenomics J
Lamas MJ et al., 2011, Use of a comprehensive panel of biomarkers to predict response to a fluorouracil-oxaliplatin regimen in patients with metastatic colorectal cancer., Pharmacogenomics
Agostini M et al., 2008, Glutathione S-transferase P1 Ile105Val polymorphism is associated with haematological toxicity in elderly rectal cancer patients receiving preoperative chemoradiotherapy., Drugs Aging
Budai B et al., 2012, Impact of SHMT1 polymorphism on the clinical outcome of patients with metastatic colorectal cancer treated with first-line FOLFIRI+bevacizumab., Pharmacogenet Genomics
Saliba J et al., 2016, Pharmacogenetic characterization of naturally occurring germline NT5C1A variants to chemotherapeutic nucleoside analogs., Pharmacogenet Genomics
Cheng L et al., 2017, Functional genetic variants of XRCC4 and ERCC1 predict survival of gastric cancer patients treated with chemotherapy by regulating the gene expression., Mol Carcinog
Le Morvan V et al., 2015, Identification of SNPs associated with response of breast cancer patients to neoadjuvant chemotherapy in the EORTC-10994 randomized phase III trial., Pharmacogenomics J
Nishio et al., 1996, Changes in markers, receptors and adhesion molecules expressed on murine hemopoietic stem cells after a single injection of 5-fluorouracil., Stem Cells
Brown CC et al., 2014, Genome-wide association and pharmacological profiling of 29 anticancer agents using lymphoblastoid cell lines., Pharmacogenomics
Tamotsu et al., 2015, Correlation of Aurora-A expression with the effect of chemoradiation therapy on esophageal squamous cell carcinoma., BMC Cancer
Hirano et al., Thymidine phosphorylase activity in transitional cell cancer: relation to histological parameters and chemosensitivity to fluorouracil-related drugs., Anticancer Res.
Yang YC et al., 2017, Association of thymidylate synthase polymorphisms with the tumor response to preoperative chemoradiotherapy in rectal cancer: a systematic review and meta-analysis., Pharmacogenomics J
Gao J et al., 2013, Polymorphism of TS 3'-UTR predicts survival of Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel., Clin Transl Oncol
Kim SR et al., 2010, Genetic polymorphisms associated with 5-Fluorouracil-induced neurotoxicity., Chemotherapy
Boulay et al., 2002, SMAD4 is a predictive marker for 5-fluorouracil-based chemotherapy in patients with colorectal cancer., Br. J. Cancer
Musashi et al., 1991, Synergistic interactions between interleukin-11 and interleukin-4 in support of proliferation of primitive hematopoietic progenitors of mice., Blood
Katayama et al., 1993, Stage-specific expression of c-kit protein by murine hematopoietic progenitors., Blood
Park et al., 2003, Inhibitory effect of 5-fluorouracil on human cytochrome P(450) isoforms in human liver microsomes., Eur. J. Clin. Pharmacol.
Sim et al., 2014, P21 and CD166 as predictive markers of poor response and outcome after fluorouracil-based chemoradiotherapy for the patients with rectal cancer., BMC Cancer
Saif et al., 2006, Dihydropyrimidine dehydrogenase deficiency in an Indian population., Cancer Chemother. Pharmacol.
Jakob et al., 2004, Thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase expression, and histological tumour regression after 5-FU-based neo-adjuvant chemoradiotherapy in rectal cancer., J. Pathol.
Araki et al., 2001, Dihydropyrimidine dehydrogenase activity and thymidylate synthase level are associated with response to 5-fluorouracil in human colorectal cancer., Kurume Med J
Hisamitsu et al., Expression of dihydropyrimidine dehydrogenase in cancer cells but not in stromal cells predicts the efficacy of fluorouracil treatment in patients with gastric carcinoma., Anticancer Res.
Ciaparrone et al., 2006, Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil., Oncology
Majounie E et al., 2020, Fluorouracil sensitivity in a head and neck squamous cell carcinoma with a somatic <i>DPYD</i> structural variant., Cold Spring Harb Mol Case Stud
Caudle et al., 2013, Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing., Clin. Pharmacol. Ther.
Herath et al., 2016, The DNA Repair Inhibitor DT01 as a Novel Therapeutic Strategy for Chemosensitization of Colorectal Liver Metastasis., Mol. Cancer Ther.
Aung et al., 2016, Testing ERBB2 p.L755S kinase domain mutation as a druggable target in a patient with advanced colorectal cancer., Cold Spring Harb Mol Case Stud
Chung et al., 2006, XRCC1 R399Q polymorphism is associated with response to platinum-based neoadjuvant chemotherapy in bulky cervical cancer., Gynecol. Oncol.
Aguilera et al., 2015, Nuclear DICKKOPF-1 as a biomarker of chemoresistance and poor clinical outcome in colorectal cancer., Oncotarget
Langer et al., 2004, [Prediction of response to neoadjuvant chemotherapy in Barrett's carcinoma by quantitative gene expression analysis]., Verh Dtsch Ges Pathol
Tajima et al., 2003, Association of gastric and intestinal phenotypic marker expression of gastric carcinomas with tumor thymidylate synthase expression and response to postoperative chemotherapy with 5-fluorouracil., J. Cancer Res. Clin. Oncol.
de Angelis et al., 2004, Molecular characterizations of derivatives of HCT116 colorectal cancer cells that are resistant to the chemotherapeutic agent 5-fluorouracil., Int. J. Oncol.
Tsunoda A et al., 2011, Associations of various gene polymorphisms with toxicity in colorectal cancer patients receiving oral uracil and tegafur plus leucovorin: a prospective study., Ann Oncol
Ichikawa W et al., 2006, Orotate phosphoribosyltransferase gene polymorphism predicts toxicity in patients treated with bolus 5-fluorouracil regimen., Clin Cancer Res
Hechtman et al., 2015, AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants., Mol. Cancer Res.
Xu et al., 2017, PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer., Clin. Cancer Res.
Bhattacharya et al., 2012, Pharmacologic synergy between dual phosphoinositide-3-kinase and mammalian target of rapamycin inhibition and 5-fluorouracil in PIK3CA mutant gastric cancer cells., Cancer Biol. Ther.
Lin CC et al., 2020, A GALNT14 rs9679162 genotype-guided therapeutic strategy for advanced hepatocellular carcinoma: systemic or hepatic arterial infusion chemotherapy., Pharmacogenomics J
Liang KH et al., 2011, GALNT14 SNP as a potential predictor of response to combination chemotherapy using 5-FU, mitoxantrone and cisplatin in advanced HCC., Pharmacogenomics
Graidist et al., 2004, Antiapoptotic protein partners fortilin and MCL1 independently protect cells from 5-fluorouracil-induced cytotoxicity., J. Biol. Chem.
Takemura et al., 2005, Enhanced Bax in oral SCC in relation to antitumor effects of chemotherapy., J. Oral Pathol. Med.
Abaza et al., Antisense oligodeoxynucleotide directed against c-myb has anticancer activity and potentiates the antiproliferative effect of conventional anticancer drugs acting by different mechanisms in human colorectal cancer cells., Tumour Biol.
Takahashi H et al., 2013, Identification of a candidate single-nucleotide polymorphism related to chemotherapeutic response through a combination of knowledge-based algorithm and hypothesis-free genomic data., J Biosci Bioeng
Alakus et al., 2009, GNAS1 T393C polymorphism is associated with histopathological response to neoadjuvant radiochemotherapy in esophageal cancer., Pharmacogenomics J.
Chéradame et al., 1997, Relevance of tumoral folylpolyglutamate synthetase and reduced folates for optimal 5-fluorouracil efficacy: experimental data., Eur. J. Cancer
Low SK et al., 2009, Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients., J Hum Genet
Kummer D et al., 2015, Dihydropyrimidinase and β-ureidopropionase gene variation and severe fluoropyrimidine-related toxicity., Pharmacogenomics
Nylén et al., 1998, Cisplatin-induced inhibition of p34cdc2 is abolished by 5-fluorouracil., Acta Oncol
Reimer T et al., 2016, SLCO1B1*5 polymorphism (rs4149056) is associated with chemotherapy-induced amenorrhea in premenopausal women with breast cancer: a prospective cohort study., BMC Cancer
Iwahashi K et al., 2004, Whole deletion of CYP2A6 gene (CYP2A6AST;4C) and smoking behavior., Neuropsychobiology
Wang H et al., 2011, Association analysis of CYP2A6 genotypes and haplotypes with 5-fluorouracil formation from tegafur in human liver microsomes., Pharmacogenomics
Tanii H et al., 2011, Population pharmacokinetic analysis of letrozole in Japanese postmenopausal women., Eur J Clin Pharmacol
Djordjevic N et al., 2010, In vivo evaluation of CYP2A6 and xanthine oxidase enzyme activities in the Serbian population., Eur J Clin Pharmacol
Ishii Y et al., 2010, Can the 2-(13)C-uracil breath test be used to predict the effect of the antitumor drug S-1?, Cancer Chemother Pharmacol
Kong SY et al., 2009, Association of CYP2A6 polymorphisms with S-1 plus docetaxel therapy outcomes in metastatic gastric cancer., Pharmacogenomics
di Iulio J et al., 2009, In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function., Pharmacogenet Genomics
Endo T et al., 2008, Genetic polymorphisms of CYP2A6 affect the in-vivo pharmacokinetics of pilocarpine., Pharmacogenet Genomics
Wang J et al., 2006, 3'-UTR polymorphism in the human CYP2A6 gene affects mRNA stability and enzyme expression., Biochem Biophys Res Commun
Gambier N et al., 2005, Association of CYP2A6*1B genetic variant with the amount of smoking in French adults from the Stanislas cohort., Pharmacogenomics J
Páez D et al., 2014, Association of common gene variants in the WNT/β-catenin pathway with colon cancer recurrence., Pharmacogenomics J
Graziano F et al., 2010, Host genetic variants in the IGF binding protein-3 impact on survival of patients with advanced gastric cancer treated with palliative chemotherapy., Pharmacogenomics
Balaji et al., 1997, Effect of 5-fluorouracil on interleukin-1 and interleukin-2 receptor expression., Biochem. Mol. Biol. Int.
Huang MY et al., 2011, Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy., Pharmacogenet Genomics
Fujishima et al., 1997, Inhibition by 5-fluorouracil of ERCC1 and gamma-glutamylcysteine synthetase messenger RNA expression in a cisplatin-resistant HST-1 human squamous carcinoma cell line., Oncol. Res.
Iwase et al., 2003, Enhanced susceptibility of oral squamous cell carcinoma cell lines to FAS-mediated apoptosis by cisplatin and 5-fluorouracil., Int. J. Cancer
Magdy T et al., 2013, ABCC11/MRP8 polymorphisms affect 5-fluorouracil-induced severe toxicity and hepatic expression., Pharmacogenomics
Szkandera J et al., 2015, LGR5 rs17109924 is a predictive genetic biomarker for time to recurrence in patients with colon cancer treated with 5-fluorouracil-based adjuvant chemotherapy., Pharmacogenomics J
Chen S et al., 2015, ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients., Pharmacogenet Genomics
Kwak et al., 2015, Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer., Cancer Discov
Banerjee et al., 1998, Role of E2F-1 in chemosensitivity., Cancer Res.
Wang L et al., 2015, Association between Polymorphisms in Vascular Endothelial Growth Factor Gene and Response to Chemotherapies in Colorectal Cancer: A Meta-Analysis., PLoS One
Scartozzi M et al., 2013, Tumor angiogenesis genotyping and efficacy of first-line chemotherapy in metastatic gastric cancer patients., Pharmacogenomics
Hansen TF et al., 2011, The predictive value of genetic variations in the vascular endothelial growth factor A gene in metastatic colorectal cancer., Pharmacogenomics J
Peeters et al., 2015, Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer., Clin. Cancer Res.
Douillard et al., 2010, Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study., J. Clin. Oncol.
Kakiuchi et al., 2004, Flow cytometric analyses on lineage-specific cell surface antigens of rat bone marrow to seek potential myelotoxic biomarkers: status after repeated dose of 5-fluorouracil., J Toxicol Sci
Zhao J et al., 2014, Association of single nucleotide polymorphisms in MTHFR and ABCG2 with the different efficacy of first-line chemotherapy in metastatic colorectal cancer., Med Oncol
De Mattia E et al., 2013, Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment., Pharmacogenet Genomics
McLeod HL et al., 2010, Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741., J Clin Oncol
Meulendijks D et al., 2016, Rs895819 in MIR27A improves the predictive value of DPYD variants to identify patients at risk of severe fluoropyrimidine-associated toxicity., Int J Cancer
Falvella FS et al., 2015, DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan., Br J Clin Pharmacol
Amstutz U et al., 2015, Polymorphisms in MIR27A Associated with Early-Onset Toxicity in Fluoropyrimidine-Based Chemotherapy., Clin Cancer Res
Offer SM et al., 2014, microRNAs miR-27a and miR-27b directly regulate liver dihydropyrimidine dehydrogenase expression through two conserved binding sites., Mol Cancer Ther
Thussbas C et al., 2006, FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer., J Clin Oncol
Fernandez-Rozadilla C et al., 2013, Pharmacogenomics in colorectal cancer: a genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration., Pharmacogenomics J
Feng et al., 2013, Cbl-b enhances sensitivity to 5-fluorouracil via EGFR- and mitochondria-mediated pathways in gastric cancer cells., Int J Mol Sci
Khrunin AV et al., 2014, Pharmacogenomic assessment of cisplatin-based chemotherapy outcomes in ovarian cancer., Pharmacogenomics
Jamieson D et al., 2011, Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy., Pharmacogenet Genomics
Kolesar JM et al., 2011, The NQO12/2 polymorphism is associated with poor overall survival in patients following resection of stages II and IIIa non-small cell lung cancer., Oncol Rep
Fagerholm R et al., 2008, NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer., Nat Genet
Siegel D et al., 2001, Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD(P)H:quinone oxidoreductase 1., Mol Pharmacol
Siegel D et al., 1999, Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1., Pharmacogenetics
Volz NB et al., 2015, Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer., Pharmacogenomics J
Di Renzo et al., 1977, Effects of some antineoplastic agents on plasma levels of corticosterone, prolactin and thyroid stimulating hormone., Arch Int Pharmacodyn Ther
Thornton et al., 2013, The unfolded protein response regulator GRP78 is a novel predictive biomarker in colorectal cancer., Int. J. Cancer
Hamad et al., 2017, Neoadjuvant Treatment With Trastuzumab and FOLFOX Induces a Complete Pathologic Response in a Metastatic ERBB2 (HER2)-Amplified Duodenal Cancer., J Natl Compr Canc Netw
Mustafa et al., 2008, 5-Fluorouracil chemotherapy affects spatial working memory and newborn neurons in the adult rat hippocampus., Eur. J. Neurosci.

FLUOROURACIL MIR27A

Interaction Score: 1.47

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26804235 25782327 25655103 24401318

Sources:
PharmGKB
FLUOROURACIL LGR5

Interaction Score: 1.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25665511

Sources:
PharmGKB
FLUOROURACIL ABCC11

Interaction Score: 1.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24024896

Sources:
PharmGKB
FLUOROURACIL WNT5B

Interaction Score: 1.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23817222

Sources:
PharmGKB
FLUOROURACIL TPT1

Interaction Score: 1.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15262975

Sources:
NCI
FLUOROURACIL ALCAM

Interaction Score: 1.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24708484

Sources:
CIViC
FLUOROURACIL MEGF11

Interaction Score: 1.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24444404

Sources:
PharmGKB
FLUOROURACIL CHN2

Interaction Score: 1.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24444404

Sources:
PharmGKB
FLUOROURACIL TMEM167A

Interaction Score: 1.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28796378

Sources:
PharmGKB
FLUOROURACIL DPYD

Interaction Score: 0.72

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16421754 15538739 11501504 15330204 17179731 31871216 23988873

Sources:
NCI CIViC TTD FDA
FLUOROURACIL ENOSF1

Interaction Score: 0.71

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27995989 27001118 23263912 20714149 17549067

Sources:
PharmGKB
FLUOROURACIL MTHFR

Interaction Score: 0.61

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26693073 18704422 29845393 29134491 27995989 27864592 27738344 27557140 26967565 26014925 25331073 24980946 24167597 23736036 23407049 23314736 20819423 20638924 20385995 19384296 18299612 18245544 17700593 12083967

Sources:
CIViC PharmGKB
FLUOROURACIL CBLB

Interaction Score: 0.59

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Indication/Tumor Type stomach cancer

Response Type decreased response

PMIDs:
24351824

Sources:
JAX-CKB
FLUOROURACIL PARD3B

Interaction Score: 0.59

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22310351

Sources:
PharmGKB
FLUOROURACIL XRCC4

Interaction Score: 0.59

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28796378

Sources:
PharmGKB
FLUOROURACIL IGFBP3

Interaction Score: 0.59

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20860465

Sources:
PharmGKB
FLUOROURACIL GALNT14

Interaction Score: 0.44

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
31611591 21635146

Sources:
PharmGKB
FLUOROURACIL ABCG1

Interaction Score: 0.39

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26352872

Sources:
PharmGKB
FLUOROURACIL XRCC3

Interaction Score: 0.39

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17549067

Sources:
PharmGKB
FLUOROURACIL DPYS

Interaction Score: 0.39

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26244261

Sources:
PharmGKB
FLUOROURACIL FPGS

Interaction Score: 0.39

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9291820

Sources:
NCI
FLUOROURACIL MYB

Interaction Score: 0.39

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15001837

Sources:
NCI
FLUOROURACIL MUC2

Interaction Score: 0.39

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
14576935

Sources:
NCI
FLUOROURACIL TYMP

Interaction Score: 0.39

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11205264 24167597

Sources:
NCI PharmGKB
FLUOROURACIL NT5C1A

Interaction Score: 0.39

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26906009

Sources:
PharmGKB
FLUOROURACIL KLC1

Interaction Score: 0.39

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17549067

Sources:
PharmGKB
FLUOROURACIL UMPS

Interaction Score: 0.35

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20647221 16818689

Sources:
PharmGKB
FLUOROURACIL EXO1

Interaction Score: 0.29

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
FLUOROURACIL RGS5

Interaction Score: 0.29

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25069475

Sources:
PharmGKB
FLUOROURACIL DLG5

Interaction Score: 0.29

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
FLUOROURACIL CDC25C

Interaction Score: 0.29

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9743457

Sources:
NCI
FLUOROURACIL DTYMK

Interaction Score: 0.29

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15067352

Sources:
NCI
FLUOROURACIL CYP2A6

Interaction Score: 0.27

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
14981342 21521021 21494765 20155256 19921195 19604090 19238117 18698229 16378601 15940289

Sources:
PharmGKB
FLUOROURACIL IL11

Interaction Score: 0.25

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
1832057 7691257

Sources:
NCI
FLUOROURACIL SHMT1

Interaction Score: 0.24

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22044939

Sources:
PharmGKB
FLUOROURACIL NQO1

Interaction Score: 0.22

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25545243 24533712 21946896 21479364 18511948 11160862 10208650

Sources:
PharmGKB
FLUOROURACIL TYMS

Interaction Score: 0.22

Interaction Types & Directionality:

other/unknown

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Thymidylate synthase inhibitor

Direct Interaction yes

PMIDs:
24450514 16563096 16609021 16596248 16538493 16719540 11752352 15353299 20628391 25544046

Sources:
DTC ClearityFoundationClinicalTrial ChemblInteractions CIViC
FLUOROURACIL ERCC1

Interaction Score: 0.21

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28796378 23314736 21057378 9268987

Sources:
NCI PharmGKB
FLUOROURACIL TP53AIP1

Interaction Score: 0.2

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
FLUOROURACIL HLA-G

Interaction Score: 0.2

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
FLUOROURACIL SLC22A16

Interaction Score: 0.2

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
FLUOROURACIL PERP

Interaction Score: 0.2

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
FLUOROURACIL GNL3

Interaction Score: 0.2

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
FLUOROURACIL REV3L

Interaction Score: 0.2

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
FLUOROURACIL DKK1

Interaction Score: 0.2

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25788273

Sources:
CIViC
FLUOROURACIL PPP2R5D

Interaction Score: 0.2

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
FLUOROURACIL FOXO1

Interaction Score: 0.2

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
FLUOROURACIL CCNK

Interaction Score: 0.2

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
FLUOROURACIL ABCC5

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26352872

Sources:
PharmGKB
FLUOROURACIL HMMR

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
FLUOROURACIL SELE

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24980946

Sources:
PharmGKB
FLUOROURACIL IL6R

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8888499

Sources:
NCI
FLUOROURACIL CDKN1A

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24708484 15067352

Sources:
NCI CIViC
FLUOROURACIL CBR3

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
FLUOROURACIL CBR1

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
FLUOROURACIL XRCC1

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23314736

Sources:
PharmGKB
FLUOROURACIL TSHB

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
603326

Sources:
NCI
FLUOROURACIL SLC19A1

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16875718

Sources:
PharmGKB
FLUOROURACIL NOS3

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29938344 25545243 19671875

Sources:
PharmGKB
FLUOROURACIL PON1

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
FLUOROURACIL PTPRC

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15206578

Sources:
NCI
FLUOROURACIL RBX1

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
FLUOROURACIL ALDH3A1

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
FLUOROURACIL SMAD4

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12237773

Sources:
CIViC
FLUOROURACIL IRS1

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
FLUOROURACIL HSPA5

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23456958

Sources:
CIViC
FLUOROURACIL E2F1

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9766655

Sources:
NCI
FLUOROURACIL ITGAL

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8888499

Sources:
NCI
FLUOROURACIL VEGFA

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25955730 24090479 20125120

Sources:
PharmGKB
FLUOROURACIL FAS

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12845662

Sources:
NCI
FLUOROURACIL APC

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Fluorouracil + Leucovorin + Trastuzumab

Indication/Tumor Type rectum adenocarcinoma

Response Type no benefit

PMIDs:
27626067

Sources:
JAX-CKB
FLUOROURACIL CCND1

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23567490

Sources:
PharmGKB
FLUOROURACIL CYP2E1

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12904931

Sources:
NCI
FLUOROURACIL GSTP1

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27995989 21449681 18540691

Sources:
PharmGKB
FLUOROURACIL FGFR4

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16822847

Sources:
PharmGKB
FLUOROURACIL CYP1B1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24958282

Sources:
PharmGKB
FLUOROURACIL IL2RA

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9238541

Sources:
NCI
FLUOROURACIL ABCC4

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19696793

Sources:
PharmGKB
FLUOROURACIL ABCG2

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24338217 24018773 20530282

Sources:
PharmGKB
FLUOROURACIL BIRC5

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15067352

Sources:
NCI
FLUOROURACIL GNAS

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19274060

Sources:
CIViC
FLUOROURACIL AURKA

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25924824

Sources:
CIViC
FLUOROURACIL BAX

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15641988

Sources:
NCI
FLUOROURACIL CYP2C8

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
FLUOROURACIL SLCO1B1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27234217

Sources:
PharmGKB
FLUOROURACIL ABCC2

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23314736

Sources:
PharmGKB
FLUOROURACIL HBB

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
FLUOROURACIL BDNF

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18702703

Sources:
NCI
FLUOROURACIL BRAF

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Fluorouracil + Leucovorin + Trastuzumab

Indication/Tumor Type rectum adenocarcinoma

Response Type no benefit

PMIDs:
26637369 27626067

Sources:
JAX-CKB
FLUOROURACIL KRAS

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Panitumumab + Oxaliplatin + Fluorouracil + Irinotecan

Indication/Tumor Type colorectal cancer

Response Type no benefit

PMIDs:
26341920 20921465

Sources:
JAX-CKB CIViC
FLUOROURACIL CYP19A1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
FLUOROURACIL PIK3CA

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Fluorouracil + Cetuximab

Indication/Tumor Type colorectal cancer

Response Type resistant

PMIDs:
25714871 28424201 22336586

Sources:
JAX-CKB
FLUOROURACIL PIK3R2

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
FLUOROURACIL ERBB2

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

combination therapy Trastuzumab + Fluorouracil + Leucovorin + Oxaliplatin

Indication/Tumor Type gastric adenocarcinoma

PMIDs:
27626067 28784859 26432108

Sources:
JAX-CKB
FLUOROURACIL NOS1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
FLUOROURACIL MET

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Trastuzumab + Fluorouracil + Leucovorin + Oxaliplatin

Indication/Tumor Type gastric adenocarcinoma

Response Type resistant

PMIDs:
26432108

Sources:
JAX-CKB
FLUOROURACIL ATM

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
FLUOROURACIL INSR

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
FLUOROURACIL TOP2A

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
FLUOROURACIL EGFR

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23816762

Sources:
PharmGKB
FLUOROURACIL PTEN

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
FLUOROURACIL ABCB1

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16892554

Sources:
NCI
FLUOROURACIL TP53

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC PharmGKB
FLUOROURACIL CYP3A4

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12904931

Sources:
NCI
FLUOROURACIL CYP2C19

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB

NCI: FLUOROURACIL

Version: 14-September-2017

Alternate Names:

C505 NCI drug code

Drug Info:

Publications:

Hisamitsu et al., Expression of dihydropyrimidine dehydrogenase in cancer cells but not in stromal cells predicts the efficacy of fluorouracil treatment in patients with gastric carcinoma., Anticancer Res.

Hirano et al., Thymidine phosphorylase activity in transitional cell cancer: relation to histological parameters and chemosensitivity to fluorouracil-related drugs., Anticancer Res.

NCI: 5-FU

Version: 14-September-2017

Alternate Names:

C505 NCI drug code

Drug Info:

Publications:

Tajima et al., 2003, Association of gastric and intestinal phenotypic marker expression of gastric carcinomas with tumor thymidylate synthase expression and response to postoperative chemotherapy with 5-fluorouracil., J. Cancer Res. Clin. Oncol.

de Angelis et al., 2004, Molecular characterizations of derivatives of HCT116 colorectal cancer cells that are resistant to the chemotherapeutic agent 5-fluorouracil., Int. J. Oncol.

Mustafa et al., 2008, 5-Fluorouracil chemotherapy affects spatial working memory and newborn neurons in the adult rat hippocampus., Eur. J. Neurosci.

NCI: 5-FLUOROURACIL

Version: 14-September-2017

Alternate Names:

C505 NCI drug code

Drug Info:

Publications:

Musashi et al., 1991, Synergistic interactions between interleukin-11 and interleukin-4 in support of proliferation of primitive hematopoietic progenitors of mice., Blood

Ciaparrone et al., 2006, Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil., Oncology

Araki et al., 2001, Dihydropyrimidine dehydrogenase activity and thymidylate synthase level are associated with response to 5-fluorouracil in human colorectal cancer., Kurume Med J

DTC: FLUOROURACIL
- Version: 02-September-2020
Alternate Names:

CHEMBL185 ChEMBL Drug ID

Drug Info:

Publications:

Pelà M et al., 2014, Optimization of peptides that target human thymidylate synthase to inhibit ovarian cancer cell growth., J Med Chem

JAX-CKB: 5-FU

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Bhattacharya et al., 2012, Pharmacologic synergy between dual phosphoinositide-3-kinase and mammalian target of rapamycin inhibition and 5-fluorouracil in PIK3CA mutant gastric cancer cells., Cancer Biol. Ther.

JAX-CKB: Fluorouracil

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Kwak et al., 2015, Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer., Cancer Discov

Peeters et al., 2015, Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer., Clin. Cancer Res.

Aung et al., 2016, Testing ERBB2 p.L755S kinase domain mutation as a druggable target in a patient with advanced colorectal cancer., Cold Spring Harb Mol Case Stud

PharmGKB: fluorouracil

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Choi JY et al., 2009, Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial., Clin Cancer Res

Geng R et al., 2014, Oxidative stress-related genetic polymorphisms are associated with the prognosis of metastatic gastric cancer patients treated with epirubicin, oxaliplatin and 5-fluorouracil combination chemotherapy., PLoS One

Kalra S et al., 2018, Association of CYP2C192 and ALDH1A11/*2 variants with disease outcome in breast cancer patients: results of a global screening array., Eur J Clin Pharmacol

CIViC: FLUOROURACIL

Version: 14-September-2020

Alternate Names:

Drug Info:

Publications:

Tamotsu et al., 2015, Correlation of Aurora-A expression with the effect of chemoradiation therapy on esophageal squamous cell carcinoma., BMC Cancer

Huang et al., 2009, The polymorphisms of TS and MTHFR predict survival of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population., Cancer Chemother. Pharmacol.

Nikas et al., 2015, A common variant in MTHFR influences response to chemoradiotherapy and recurrence of rectal cancer., Am J Cancer Res

TTD: Fluorouracil
- Version: 2020.06.01
Alternate Names:

D05LEO TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL185
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
FDA: Fluorouracil
- Version: 04-September-2020
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL185
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:
ClearityFoundationClinicalTrial: FLUOROURACIL
- Version: 15-June-2013
Alternate Names:

Drug Info:

Publications:
ClearityFoundationClinicalTrial: 5-FLUOROURACIL
- Version: 15-June-2013
Alternate Names:

Drug Info:

Publications:

Evidence Type	Actionable
Indication/Tumor Type	stomach cancer
Response Type	decreased response

Mechanism of Interaction	Thymidylate synthase inhibitor
Direct Interaction	yes

combination therapy	Fluorouracil + Leucovorin + Trastuzumab
Indication/Tumor Type	rectum adenocarcinoma
Response Type	no benefit

combination therapy	Panitumumab + Oxaliplatin + Fluorouracil + Irinotecan
Indication/Tumor Type	colorectal cancer
Response Type	no benefit

combination therapy	Fluorouracil + Cetuximab
Indication/Tumor Type	colorectal cancer
Response Type	resistant

combination therapy	Trastuzumab + Fluorouracil + Leucovorin + Oxaliplatin
Indication/Tumor Type	gastric adenocarcinoma
Response Type	resistant

FLUOROURACIL Drug Record

FLUOROURACIL chembl:CHEMBL185 ApprovedAntineoplasticImmunotherapy

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26804235 25782327 25655103 24401318

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25665511

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24024896

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23817222

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15262975

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24708484

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24444404

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24444404

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28796378

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16421754 15538739 11501504 15330204 17179731 31871216 23988873

Sources: NCI CIViC TTD FDA

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27995989 27001118 23263912 20714149 17549067

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26693073 18704422 29845393 29134491 27995989 27864592 27738344 27557140 26967565 26014925 25331073 24980946 24167597 23736036 23407049 23314736 20819423 20638924 20385995 19384296 18299612 18245544 17700593 12083967

Sources: CIViC PharmGKB

Interaction Types & Directionality: n/a

Interaction Info: Evidence Type Actionable Indication/Tumor Type stomach cancer Response Type decreased response

PMIDs: 24351824

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22310351

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28796378

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 20860465

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 31611591 21635146

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26352872

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17549067

Interaction Types & Directionality:

n/a

PMIDs:
26804235 25782327 25655103 24401318

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
25665511

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
24024896

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
23817222

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
15262975

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
24708484

Sources:
CIViC

Interaction Types & Directionality:

n/a

PMIDs:
24444404

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
24444404

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
28796378

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
16421754 15538739 11501504 15330204 17179731 31871216 23988873

Sources:
NCI CIViC TTD FDA

Interaction Types & Directionality:

n/a

PMIDs:
27995989 27001118 23263912 20714149 17549067

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
26693073 18704422 29845393 29134491 27995989 27864592 27738344 27557140 26967565 26014925 25331073 24980946 24167597 23736036 23407049 23314736 20819423 20638924 20385995 19384296 18299612 18245544 17700593 12083967

Sources:
CIViC PharmGKB

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Indication/Tumor Type stomach cancer

Response Type decreased response

PMIDs:
24351824

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
22310351

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
28796378

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
20860465

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
31611591 21635146

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
26352872

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
17549067

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
26244261

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
9291820

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
15001837

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
14576935

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
11205264 24167597

Sources:
NCI PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
26906009

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
17549067

Sources:
PharmGKB

Interaction Types & Directionality:

n/a